Get the Stockscreener App
0.7943
6.77%
-0.0577
After Hours:
.80
0.0057
+0.72%
Immunic Inc stock is traded at $0.7943, with a volume of 2.25M.
It is down -6.77% in the last 24 hours and down -6.79% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.852
Open:
$0.8706
24h Volume:
2.25M
Relative Volume:
1.68
Market Cap:
$78.36M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3764
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
+4.38%
1M Performance:
-6.79%
6M Performance:
-31.53%
1Y Performance:
-46.69%
1-Day Range:
$0.783
$0.888
1-Week Range:
$0.7761
$0.90
52-Week Range:
$0.561
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.7943 | 86.02M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
What machine learning models say about Immunic Inc.2025 Growth vs Value & Smart Allocation Stock Reports - Newser
Key metrics from Immunic Inc.’s quarterly dataJuly 2025 Levels & Technical Buy Zone Confirmations - Newser
What moving averages say about Immunic Inc.Earnings Recap Summary & Real-Time Volume Analysis Alerts - Newser
What’s next for Immunic Inc. stock pricePrice Action & Stepwise Entry/Exit Trade Alerts - Newser
Can trapped investors hope for a rebound in Immunic Inc.July 2025 Big Picture & Safe Entry Point Identification - Newser
Using flow based indicators on Immunic Inc.July 2025 Catalysts & Daily Risk Controlled Trade Plans - Newser
Visual trend scoring systems applied to Immunic Inc.Weekly Trade Summary & Real-Time Sentiment Analysis - Newser
Visual analytics tools that track Immunic Inc. performanceMarket Performance Recap & Stock Timing and Entry Methods - Newser
Combining machine learning predictions for Immunic Inc.Analyst Downgrade & Stepwise Entry and Exit Trade Signals - Newser
Market reaction to Immunic Inc.’s recent newsTake Profit & Daily Growth Stock Investment Tips - Newser
Is Immunic Inc. a candidate for recovery playPortfolio Risk Summary & Stock Market Timing Techniques - Newser
Analyzing drawdowns of Immunic Inc. with statistical toolsPortfolio Gains Report & Community Driven Trade Alerts - Newser
Identifying reversal signals in Immunic Inc.2025 Technical Overview & Safe Capital Growth Stock Tips - Newser
Intraday pattern recognizer results for Immunic Inc.July 2025 Weekly Recap & Trade Opportunity Analysis - Newser
Multi asset correlation models including Immunic Inc.2025 Fundamental Recap & Reliable Price Breakout Alerts - Newser
Will Immunic Inc. continue its uptrendQuarterly Profit Review & Capital Efficiency Focused Strategies - Newser
heatmap analysis for immunic inc. and competitorsJuly 2025 News Drivers & Weekly High Return Stock Forecasts - Newser
Immunic receives patent for multiple sclerosis treatment dose strengths By Investing.com - Investing.com Australia
Analyzing recovery setups for Immunic Inc. investorsPortfolio Risk Report & Reliable Entry Point Alerts - Newser
Immunic receives notice of allowance for vidofludimus calcium patent - MSN
Backtesting results for Immunic Inc. trading strategiesJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Using Ichimoku Cloud for Immunic Inc. technicalsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MS - Proactive financial news
Immunic receives patent for multiple sclerosis treatment dose strengths - Investing.com
Immunic receives notice of allowance for US Patent protecting vidofludimus calcium's dose strengths - MarketScreener
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - Ariva
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PR Newswire
Advanced analytics toolkit walkthrough for Immunic Inc.Bond Market & Reliable Price Breakout Signals - Newser
B. Riley Forecasts Immunic's Q3 Earnings (NASDAQ:IMUX) - MarketBeat
key metrics from immunic inc.’s quarterly dataTrade Volume Report & Risk Controlled Stock Pick Alerts - Newser
How to use Fibonacci retracement on Immunic Inc.Weekly Investment Report & Safe Capital Growth Tips - Newser
Will Immunic Inc. outperform the marketQuarterly Profit Review & Real-Time Stock Entry Alerts - Newser
Is it too late to sell Immunic Inc.Earnings Overview Report & Stock Market Timing Techniques - Newser
What candlestick patterns are forming on Immunic Inc.2025 Support & Resistance & Safe Entry Zone Tips - Newser
Immunic at H.C. Wainwright: Vidofludimus Calcium’s Promise in MS - Investing.com
Immunic at H.C. Wainwright: Vidofludimus Calcium’s Promise in MS By Investing.com - Investing.com South Africa
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):